Novo Nordisk confident of amycretin obesity drug launch this decade
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 39.43 +0.37 (0.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.06 | 52 Week High | $59.00 | |||
| Open | $39.39 | 52 Week Low | $32.80 | |||
| Day High | $39.77 | P/E | N/A | |||
| Day Low | $39.24 | EPS | $0.00 | |||
| Volume | 8,555,835 | |||||
